Afm24 is a human, tetravalent bispecific antibody targeting EGFR on tumor cells and the human low affinity IgG Fc region receptor IIIA (FCGR3A; CD16A) on innate immune cells. It enhances NK cell-mediated cytotoxicity and macrophage-driven phagocytosis, making it a promising immunotherapy with reduced EGFR-related toxicities for cancer treatment. M.W 196.34 kDa.